Sarroff Fund Adds 24,033 PetVivo Shares, Signals Long‑Term Confidence as Board Awards Restricted Shares to Directors.

A.L. Sarroff Fund, LLC Buys 24,033 Shares of PetVivo Holdings: What It Means for Investors

The latest Form 4 filing shows that A.L. Sarroff Fund, LLC, a significant shareholder in PetVivo Holdings Inc., added 24,033 common shares to its position on March 23, 2026, paying $0.68 per share. The purchase brings the fund’s holdings to 10,202,229 shares—a 0.23 % stake in the company—at a price very close to the market value of $0.75. The transaction is a routine buy that does not trigger a 10‑2 market‑wide sale or a 13 G report, but it is part of a larger pattern of frequent, relatively modest purchases by the fund that have kept its ownership relatively stable over the past year.

Implications of the Current Deal and Recent Insider Activity

PetVivo’s stock has been highly volatile, swinging from a 52‑week low of $0.45 to a high of $1.69, while its market cap sits just under $24 million. In this environment, an incremental buy by a well‑connected institutional investor can be a subtle signal. The fund’s purchases have been spread evenly throughout 2025 and early 2026, with no large sell‑offs except a 60,000‑share sale on December 31, 2025, likely a tax‑loss harvesting move. The timing of the March 23 purchase—just after the board’s award of restricted shares to several directors—may suggest that the fund is positioning itself for potential upside as those directors may benefit from future earnings growth or a strategic shift in the company’s product pipeline.

What Investors Should Take Away

1. Steady, Long‑Term Positioning – The fund’s holdings have grown from 8.4 million in May 2025 to over 10.2 million by March 2026, a roughly 21 % increase. This steady accumulation implies confidence in PetVivo’s long‑term prospects, especially as the company develops its arthritic disease‑modifying devices for companion animals.

2. Absence of Aggressive Trading – No large block trades or 13 G filings have been triggered. The fund is not a short‑term trader but a long‑term investor, which may reassure risk‑averse shareholders that the company is not being targeted by speculative short sellers.

3. Potential for Value Creation – With a negative P/E of –1.94 and a 52‑week high of $1.69, the share price remains undervalued relative to its assets and product pipeline. If the company can successfully commercialize its next generation of devices, the stock could see significant upside—something the Sarroff Fund appears prepared to support.

A.L. Sarroff Fund, LLC: A Profile of an Investor

A.L. Sarroff Fund, LLC is a private investment vehicle led by Alan L. Sarroff, a seasoned executive with a history in biotech and private equity. The fund’s trading activity at PetVivo is characterized by:

• Consistent Small‑Block Buying – The bulk of its purchases are between 1,000 and 10,000 shares, executed at market or slightly below market prices. This suggests a disciplined approach aimed at minimizing market impact.

• Focus on Emerging Biotech – The fund has previously invested in niche biotech platforms that deliver high upside if clinical milestones are met. PetVivo’s focus on veterinary therapeutics aligns with this niche.

• Risk Management via Diversification – In addition to PetVivo, the Sarroff Fund holds positions in other mid‑cap health‑care companies, reducing idiosyncratic risk.

The fund’s recent purchase of 24,033 shares may be viewed as a “buy the dip” move, capitalizing on a price that sits near the lower end of the company’s recent trading range. For investors, it signals that a serious, long‑term player is adding to its stake at a time when the stock may still have room to grow.

Looking Ahead

PetVivo’s board is currently focused on scaling manufacturing and pursuing regulatory approvals for its next‑generation arthritic device. The company’s revenue pipeline is modest, but the niche market of companion‑animal therapeutics is growing. With the Sarroff Fund maintaining a stable, increasing stake, and other directors receiving restricted shares for board service, the company is likely to retain experienced leadership and strategic focus.

For investors, the key takeaways are:

• Monitor the Fund’s Trading Pace – Continued small‑block purchases may indicate confidence in near‑term product launches.
• Watch for Milestones – Regulatory approvals or commercialization of new devices could trigger a rally.
• Consider the Valuation Gap – The stock remains below its 52‑week high, offering a potential upside for long‑term investors.

In sum, the recent transaction by A.L. Sarroff Fund, LLC is a modest addition that reinforces its long‑term commitment to PetVivo Holdings. It reflects a patient, measured investment style that could bode well for shareholders if the company’s product pipeline delivers on its promise.